# LYMPHIR (lymphir) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lymphir

> The FDA approved LYMPHIR (lymphir), sponsored by CITIUS ONCOLOGY, INC. (CTOR), on Dec 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | LYMPHIR (lymphir) |
| Codes |  |
| Sponsor | CITIUS ONCOLOGY, INC. (CTOR) https://sec-api.dev/companies/ctor/catalysts |
| Indications | cutaneous t-cell lymphoma, with relapsed or refractory ctcl, with relapsed or refractory stage i-iii ctcl, [high risk relapsed or refractory diffuse large b cell lymphoma](https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma), with relapsed or refractory stage |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 28, 2023: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2024-12-27, last confirmed 2024-12-27.
- SEC Form 10-K (accession 0001213900-24-113150): "In December 2022, a Biologics License Application ("BLA") for LYMPHIR was accepted for filing with the FDA and a PDUFA goal date was set for July 28, 2023." https://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm
- SEC Form 10-K (accession 0001213900-24-113149): "In December 2022, a biologics license application ("BLA") for LYMPHIR was accepted for filing with the FDA and a PDUFA goal date was set for July 28, 2023." https://www.sec.gov/Archives/edgar/data/1506251/000121390024113149/ea0225656-10k_citius.htm
- SEC Form 10-K (accession 0001213900-25-125331): "As an example, in response to the submission of our BLA for LYMPHIR, the FDA issued a CRL on July 28, 2023." https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/ea0270097-10k_citius.htm

### July 29, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2024-12-27, last confirmed 2026-04-24.
- SEC Form 10-K (accession 0001213900-25-125331): "As an example, in response to the submission of our BLA for LYMPHIR, the FDA issued a CRL on July 28, 2023." https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/ea0270097-10k_citius.htm
- SEC Form 10-K (accession 0001213900-24-113150): "On July 29, 2023, we received a Complete Response Letter, ("CRL") from the FDA regarding the BLA seeking approval for LYMPHIR." https://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm
- SEC prospectus (424B) (accession 0001213900-25-064848): "As an example, in July 2023, the FDA issued a CRL to our BLA for LYMPHIR, which required us to incorporate enhanced product testing and additional controls and which caused a delay of six months before we could resubmit the" https://www.sec.gov/Archives/edgar/data/1851484/000121390025064848/ea0249150-424b4_citius.htm
- SEC Form 10-K (accession 0001213900-24-113150): "As an example, in July 2023, the FDA issued a CRL to our BLA for LYMPHIR, which required us to incorporate enhanced product testing and additional controls and which caused a delay of six months before we could resubmit the BLA;" https://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm
- SEC prospectus (424B) (accession 0001213900-25-064848): "On July 29, 2023, we received a Complete Response Letter, ("CRL")" https://www.sec.gov/Archives/edgar/data/1851484/000121390025064848/ea0249150-424b4_citius.htm
- SEC Form 10-K (accession 0001213900-25-125331): "In July 2023, the FDA issued a complete response letter ("CRL") requiring the Company to incorporate enhanced product testing and additional controls agreed to with the FDA during the market application review." https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/ea0270097-10k_citius.htm
- SEC prospectus (424B) (accession 0001213900-25-064848): "In July 2023, the FDA issued a complete response letter ("CRL") requiring the Company to incorporate enhanced product testing and additional controls agreed to with the FDA during the market application review." https://www.sec.gov/Archives/edgar/data/1851484/000121390025064848/ea0249150-424b4_citius.htm
- SEC Form 10-K (accession 0001213900-24-113150): "In July 2023, the FDA issued a complete response letter ("CRL") requiring the Company to incorporate enhanced product testing and additional controls agreed to with the FDA during the market application review." https://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm
- SEC Form 10-K (accession 0001213900-25-125333): "As an example, in response to the submission of our BLA for LYMPHIR, the FDA issued a complete response letter ("CRL") on July 28, 2023." https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/ea0270098-10k_citius.htm
- SEC prospectus (424B) (accession 0001213900-25-053274): "On July 29, 2023, we received a complete response letter from the FDA regarding the BLA seeking approval for LYMPHIR." https://www.sec.gov/Archives/edgar/data/1506251/000121390025053274/ea0245310-424b5_citius.htm
- SEC Form 10-K (accession 0001213900-24-113149): "As an example, in response to the submission of our BLA for LYMPHIR, the FDA issued a complete response letter ("CRL") on July 28, 2023." https://www.sec.gov/Archives/edgar/data/1506251/000121390024113149/ea0225656-10k_citius.htm
- SEC prospectus (424B) (accession 0001213900-26-047296): "In July 2023, we received a complete response letter from the FDA regarding the BLA seeking approval for LYMPHIR." https://www.sec.gov/Archives/edgar/data/1506251/000121390026047296/ea0287618-424b5_citius.htm

### Sep 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2024-12-27, last confirmed 2025-12-23.
- SEC Form 10-K (accession 0001213900-25-125331): "In September 2023, we announced that the FDA had agreed with our plans to address the requirements outlined in the CRL, which guidance provided us with a path for completing the necessary activities to support the resubmission of the BLA for LYMPHIR and we received approval from the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/ea0270097-10k_citius.htm
- SEC Form 10-K (accession 0001213900-25-125333): "In September 2023, we announced that the FDA had agreed with our plans to address the requirements outlined in the CRL, which guidance provided us with a path for completing the necessary activities to support the resubmission of the BLA for LYMPHIR and we received approval from the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/ea0270098-10k_citius.htm
- SEC Form 10-K (accession 0001213900-24-113149): "In September 2023, we announced that the FDA had agreed with our plans to address the requirements outlined in the CRL, which guidance provided us with a path for completing the necessary activities to support the resubmission of the BLA for LYMPHIR and we received approval from the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1506251/000121390024113149/ea0225656-10k_citius.htm

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: with relapsed or refractory CTCL.
- First seen 2024-11-12, last confirmed 2025-12-01.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-010748): "LYMPHIR was approved by the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390025010748/ea023015701ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-001407): "LYMPHIR was approved by the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390025001407/ea022698401ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-000953): "LYMPHIR was approved by the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390025000953/ea022666501ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-24-096269): "LYMPHIR was approved by the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea022066601ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-116764): "In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory Stage I-III CTCL who had had at least one prior systemic therapy." https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/ea026756001ex99-2_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-116764): "In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of adults with relapsed or refractory Stage" https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/ea026756001ex99-2_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-086568): "In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy." https://www.sec.gov/Archives/edgar/data/1851484/000121390025086568/ea025672301ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-086568): "In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma." https://www.sec.gov/Archives/edgar/data/1851484/000121390025086568/ea025672301ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-065334): "In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy." https://www.sec.gov/Archives/edgar/data/1851484/000121390025065334/ea024929201ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-065334): "In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma." https://www.sec.gov/Archives/edgar/data/1851484/000121390025065334/ea024929201ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-055182): "In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy." https://www.sec.gov/Archives/edgar/data/1851484/000121390025055182/ea024593301ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-055182): "In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma." https://www.sec.gov/Archives/edgar/data/1851484/000121390025055182/ea024593301ex99-1_citius.htm

### August 13, 2024: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2024-12-27, last confirmed 2025-12-23.
- SEC Form 10-K (accession 0001213900-25-125331): "The FDA assigned a PDUFA goal date of August 13, 2024 and approved LYMPHIR on August 8, 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/ea0270097-10k_citius.htm
- SEC prospectus (424B) (accession 0001213900-25-064848): "The FDA assigned a PDUFA goal date of August 13, 2024 and approved LYMPHIR on August 8, 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390025064848/ea0249150-424b4_citius.htm
- SEC Form 10-K (accession 0001213900-24-113150): "The FDA assigned a PDUFA goal date of August 13, 2024 and approved LYMPHIR on August 8, 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm
- SEC Form 10-K (accession 0001213900-25-125333): "The FDA assigned a PDUFA goal date of August 13, 2024 and approved LYMPHIR on August 8, 2024." https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/ea0270098-10k_citius.htm
- SEC Form 10-K (accession 0001213900-24-113149): "The FDA assigned a PDUFA goal date of August 13, 2024 and approved LYMPHIR on August 8, 2024." https://www.sec.gov/Archives/edgar/data/1506251/000121390024113149/ea0225656-10k_citius.htm

### Dec 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2026-08-14, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-115964): "LYMPHIR was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026115964/ea031092801ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-112477): "LYMPHIR was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026112477/ea030934701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-090182): "LYMPHIR was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/ea030222601ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-115962): "LYMPHIR was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1506251/000121390026115962/ea031093101ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-112478): "LYMPHIR was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1506251/000121390026112478/ea030934501ex99-1.htm

### March 4, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1. Indication: high risk relapsed or refractory diffuse large B cell lymphoma.
- First seen 2026-05-15, last confirmed 2026-08-14.
- SEC Form 10-Q (accession 0001213900-26-090184): "On March 4, 2026, we announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to commercial CD19 directed" https://www.sec.gov/Archives/edgar/data/1851484/000121390026090184/ea0301678-10q_citius.htm
- SEC Form 10-Q (accession 0001213900-26-057841): "On March 4, 2026, we announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to commercial CD19 directed" https://www.sec.gov/Archives/edgar/data/1851484/000121390026057841/ea0290553-10q_citius.htm
- SEC Form 10-Q (accession 0001213900-26-090185): "On March 4, 2026, Citius Oncology announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." https://www.sec.gov/Archives/edgar/data/1506251/000121390026090185/ea0301919-10q_citius.htm
- SEC Form 10-Q (accession 0001213900-26-057842): "On March 4, 2026, Citius Oncology announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." https://www.sec.gov/Archives/edgar/data/1506251/000121390026057842/ea0290552-10q_citius.htm

### March 10, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-03-10, last confirmed 2026-03-10.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025464): "Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers" https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea028066301ex99-1.htm
- SEC Form 8-K (accession 0001213900-26-025464): "On March 10, 2026, we issued a press release announcing positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea0280663-8k_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025464): "Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea028066301ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025459): "Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers" https://www.sec.gov/Archives/edgar/data/1506251/000121390026025459/ea028066401ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025459): "Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." https://www.sec.gov/Archives/edgar/data/1506251/000121390026025459/ea028066401ex99-1.htm

### May 15, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-05-15, last confirmed 2026-05-15.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-057883): "Announced positive topline results from two investigator-initiated Phase 1 studies evaluating LYMPHIR in combination settings, including:" https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm

## Same indication

- [Denileukin](https://sec-api.dev/pdufa/denileukin) (CTOR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lymphir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LYMPHIR (lymphir) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lymphir

```bibtex
@misc{secapidev_pdufa_lymphir_20261116,
  title        = {LYMPHIR (lymphir) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lymphir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lymphir_20261116","title":"LYMPHIR (lymphir) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lymphir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
